Baseline plasma levels of soluble PD-1, PD-L1, and BTN3A1 predict response to nivolumab treatment in patients with metastatic renal cell carcinoma: a step toward a biomarker for therapeutic decisions.
BTN2A1
BTN3A1
PD-1
PD-L1
butyrophilins
circulating immune checkpoints
immunotherapy response
predictive biomarker
renal cell carcinoma
soluble immune-checkpoints
Journal
Oncoimmunology
ISSN: 2162-4011
Titre abrégé: Oncoimmunology
Pays: United States
ID NLM: 101570526
Informations de publication
Date de publication:
27 10 2020
27 10 2020
Historique:
entrez:
12
11
2020
pubmed:
13
11
2020
medline:
13
11
2020
Statut:
epublish
Résumé
Despite a proportion of renal cancer patients can experiment marked and durable responses to immune-checkpoint inhibitors, the treatment efficacy is widely variable and identifying the patient who will benefit from immunotherapy remains an issue. We performed a prospective study to investigate if soluble forms of the immune-checkpoints PD-1 (sPD-1), PD-L1 (sPD-L1), pan-BTN3As, BTN3A1, and BTN2A1, could be candidate to predict the response to immune-checkpoint blockade therapy. We evaluated the plasma levels in a learning cohort of metastatic clear cell renal carcinoma (mccRCC) patients treated with the anti-PD-1 agent nivolumab by
Identifiants
pubmed: 33178494
doi: 10.1080/2162402X.2020.1832348
pii: 1832348
pmc: PMC7595592
doi:
Substances chimiques
Antigens, CD
0
B7-H1 Antigen
0
BTN3A1 protein, human
0
Butyrophilins
0
Programmed Cell Death 1 Receptor
0
Nivolumab
31YO63LBSN
Types de publication
Journal Article
Langues
eng
Pagination
1832348Informations de copyright
© 2020 The Author(s). Published with license by Taylor & Francis Group, LLC.
Références
Ther Adv Med Oncol. 2019 Aug 05;11:1758835919861905
pubmed: 31428205
N Engl J Med. 2015 Nov 5;373(19):1803-13
pubmed: 26406148
Nat Rev Cancer. 2015 Aug;15(8):457-72
pubmed: 26205340
Cancer J. 2018 Jan/Feb;24(1):41-46
pubmed: 29360727
J Investig Med. 2019 Jan;67(1):1-10
pubmed: 30455223
Ann Oncol. 2020 Aug;31(8):1030-1039
pubmed: 32339648
Ther Adv Med Oncol. 2019 May 13;11:1758835919848872
pubmed: 31205506
Br J Cancer. 2013 Feb 19;108(3):479-85
pubmed: 23299535
Lancet Oncol. 2019 Oct;20(10):1370-1385
pubmed: 31427204
Bull Exp Biol Med. 2019 Jan;166(3):353-357
pubmed: 30627905
JAMA Oncol. 2019 Mar 1;5(3):411-421
pubmed: 30476955
Eur J Cancer. 2016 May;59:152-159
pubmed: 27039170
Leukemia. 2014 Dec;28(12):2367-75
pubmed: 24732592
Oncoimmunology. 2019 Feb 3;8(4):e1561120
pubmed: 30906655
J Cancer Res Clin Oncol. 2019 Feb;145(2):303-312
pubmed: 30267213
Int J Mol Sci. 2017 Oct 20;18(10):
pubmed: 29053609
Urology. 1974 Jun;3(6):777-8
pubmed: 4836344
N Engl J Med. 2019 Mar 21;380(12):1116-1127
pubmed: 30779529
J Immunother Cancer. 2019 Nov 29;7(1):334
pubmed: 31783776
Ann Oncol. 2016 Aug;27(8):1482-92
pubmed: 27069014
J Cancer Res Clin Oncol. 2016 Aug;142(8):1727-38
pubmed: 27256004
Int J Mol Sci. 2019 Apr 17;20(8):
pubmed: 30999623
Cancer Immunol Res. 2017 Jun;5(6):480-492
pubmed: 28522460
Cancer Treat Rev. 2018 Nov;70:127-137
pubmed: 30173085
N Engl J Med. 2018 Apr 05;378(14):1277-1290
pubmed: 29562145
J Pathol. 2018 Apr;244(5):525-537
pubmed: 29266437
Oncotarget. 2016 Apr 19;7(16):21259-71
pubmed: 26872372
Lung Cancer. 2017 Feb;104:1-6
pubmed: 28212990
J Clin Oncol. 2015 May 1;33(13):1430-7
pubmed: 25452452
Clin Cancer Res. 2011 Apr 1;17(7):1915-23
pubmed: 21355078
Adv Ther. 2019 Oct;36(10):2600-2617
pubmed: 31432460
Oncoimmunology. 2016 Apr 25;5(10):e1146843
pubmed: 27853633
Oncoimmunology. 2017 Sep 21;7(1):e1372080
pubmed: 29296524
Cancers (Basel). 2020 Feb 18;12(2):
pubmed: 32085544
Nat Rev Cancer. 2012 Mar 22;12(4):252-64
pubmed: 22437870
Nat Rev Nephrol. 2017 Aug;13(8):496-511
pubmed: 28691713
Oncotarget. 2015 Dec 1;6(38):41228-36
pubmed: 26515600
Front Oncol. 2019 Jun 14;9:490
pubmed: 31259150
Ann Surg Oncol. 2019 Mar;26(3):876-883
pubmed: 30565045
Cell Immunol. 2019 Sep;343:103753
pubmed: 29395859
Oncotarget. 2016 Nov 22;7(47):76604-76612
pubmed: 27780932